The King of Kings
A bold move?
Over the last couple of years we have been quietly interviewing the various biotech and pharma players in the protein degradation niche and exploring their numerous approaches and pipelines.
In the latest company interview, we take look at C4 Therapeutics (C4T), who are a relatively young company with preclinical data at AACR next month, plus their first clinical trial opening imminently, both excellent achievements in a relatively short space of time.
So what are C4T about and where do they seem themselves positioned? What are their goals and what should we be expecting to see/hear from them? Do they have a shot at achieving their lofty aims?
To find out drop in and catch up on our latest CSO interview…
To learn more about C4 Therapeutics and get a heads up on our latest oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
